CBS 2019
CBSMD教育中心
中 文

ASCVD Prevention

Abstract

Recommended Article

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy From Focal Lipid Storage to Systemic Inflammation Colchicine Reduces Cardiovascular Events in Chronic Coronary Disease Sequence variations in PCSK9, low LDL, and protection against coronary heart disease The Prevalence of Myocardial Bridging Associated with Coronary Endothelial Dysfunction in Patients with Chest Pain and Non-Obstructive Coronary Artery Disease Endocardium Minimally Contributes to Coronary Endothelium in the Embryonic Ventricular Free Walls Noninvasive Nuclear SPECT Myocardial Blood Flow Quantitation to Guide Management for Coronary Artery Disease Impact of Abnormal Coronary Reactivity on Long-Term Clinical Outcomes in Women

Review ArticleVolume 75, Issue 20, May 2020

JOURNAL:JACC Article Link

Summary of Updated Recommendations for Primary Prevention of Cardiovascular Disease in Women: JACC State-of-the-Art Review

L Cho, M Davis, and for the ACC CVD Womens Committee Members. Keywords: adverse pregnancy outcomes; aspirin; atrial fibrillation; cardiovascular disease; gestational diabetes

ABSTRACT

Cardiovascular disease (CVD) remains the leading cause of morbidity and mortality for women in the United States and worldwide. There has been no American College of Cardiology (ACC)/American Heart Association guideline update specifically for the prevention of CVD in women since 2011. Since then, the body of sex-specific data has grown, in addition to updated hypertension, cholesterol, diabetes, atrial fibrillation, and primary prevention guidelines. The ACC CVD in Women Committee undertook a review of the recent guidelines and major studies to summarize recommendations pertinent to women. In this update, the authors address special topics, particularly the risk factors and treatments that have led to some controversies and confusion. Specifically, sex-related risk factors, hypertension, diabetes, hyperlipidemia, anticoagulation for atrial fibrillation, use of aspirin, perimenopausal hormone therapy, and psychosocial issues are highlighted.